The U.S. FDA has expanded the indication for pirtobrutinib (Jaypirca; Eli Lilly and Company) to include adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. The October 2, 2026 decision moves the non-covalent Bruton tyrosine kinase inhibitor into first-line treatment for an eligible CLL/SLL population.
Pirtobrutinib was already approved in the United States for relapsed or refractory CLL/SLL after prior treatment with a covalent BTK inhibitor.
Approval Was Based on BRUIN CLL-313
BRUIN CLL-313 was a global, randomized, open-label phase III trial enrolling 282 patients with previously untreated CLL/SLL without 17p deletion. Patients were randomized 1:1 to pirtobrutinib 200 mg orally once daily until disease progression or unacceptable toxicity, or to BR. The primary endpoint was progression-free survival assessed by a blinded independent review committee. Secondary endpoints included response, duration of response, overall survival, time to next treatment, safety, and patient-reported outcomes.
The results can’t be extrapolated to previously untreated patients with known del(17p), a biologically high-risk group that needs separate evidence.
Pirtobrutinib is a highly selective non-covalent BTK inhibitor that binds both wild-type and C481-mutated BTK. That mechanism made it useful after covalent BTK inhibitor exposure, when acquired BTK alterations can lead to resistance. BRUIN CLL-313 tested the same drug before that selective pressure occurs.
Pirtobrutinib Significantly Improved Progression-Free Survival
At a median follow-up of 28 months, pirtobrutinib significantly improved independent review committee-assessed PFS compared with BR, with an 80% relative reduction in the risk of progression or death. Median PFS had not been reached with pirtobrutinib and was 33.5 months with BR.
The overall response rate was 94% with pirtobrutinib and 81% with BR. Complete responses were reported in 13% and 21%, respectively, with partial responses accounting for most responses in the pirtobrutinib group. Overall survival and the durability of disease control will need longer follow-up.
What the BR Comparator Means for Clinical Interpretation
BR is an active historical CLL regimen, but BTK inhibitors and fixed-duration venetoclax-based combinations have reduced the role of chemoimmunotherapy, particularly in older patients.
BRUIN CLL-313 provides randomized phase III evidence that first-line pirtobrutinib is superior to BR in patients without 17p deletion. It includes no head-to-head comparison with acalabrutinib, zanubrutinib, venetoclax-obinutuzumab, or newer targeted combinations. Choosing among these strategies still depends on continuous versus fixed-duration therapy, cardiovascular risk, drug interactions, comorbidities, molecular risk, and patient preference.
A separate phase III trial, BRUIN CLL-314, is comparing pirtobrutinib directly with ibrutinib in a BTK inhibitor-naive population that includes both treatment-naive and previously treated patients. The BRUIN program also includes randomized studies of pirtobrutinib after covalent BTK inhibition and in fixed-duration venetoclax-containing therapy.
Safety Remained Consistent With the Known Pirtobrutinib Profile
In BRUIN CLL-313, serious adverse reactions occurred in 28% of patients receiving pirtobrutinib. Adverse reactions led to dose reduction in 3.6% and permanent discontinuation in 4.3%.
Atrial fibrillation or flutter occurred in 1.4% of pirtobrutinib-treated patients. Cardiovascular toxicity has been an important consideration with BTK inhibition, but the trial excluded patients with significant cardiovascular disease, so the low rate may not apply to less-selected populations.
Across the broader pirtobrutinib program, the prescribing information includes warnings for serious infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, and hepatotoxicity including drug-induced liver injury. These matter more in an earlier-line population potentially facing prolonged exposure.
First-Line Use Raises Sequencing and Duration Questions
Using pirtobrutinib first means clinicians need evidence on subsequent covalent BTK inhibition, BCL2 inhibition, and other therapies after progression on a non-covalent BTK inhibitor. The consequences of choosing a non-covalent BTK inhibitor as the first BTK-directed therapy may differ from the better-established sequence.
Pirtobrutinib in BRUIN CLL-313 was given continuously until progression or unacceptable toxicity. That is a different treatment model from fixed-duration venetoclax-containing regimens, where a defined treatment-free interval is part of the strategy.
You can also read:
